ANZ 100

Drug Profile

ANZ 100

Alternative Names: ANZ-100; CRS-100

Latest Information Update: 07 Jan 2016

Price : $50

At a glance

  • Originator Cerus Corporation
  • Developer Aduro BioTech
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Liver cancer

Most Recent Events

  • 05 Jan 2016 Aduro BioTech receives patent allowance for its LADD platform in USA
  • 08 Feb 2012 Discontinued - Phase-I for Liver cancer in USA (IV)
  • 08 Feb 2012 ANZ 100 is available for licensing in World as of 08 Feb 2012. http://www.adurobiotech.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top